From what I have gleaned, they still don't compete if they target the same cancer. Mettl3 and FTO target different pathways and gene mutations. They are opposing mechanisms in the m6a regulators.
This is why cancer is so hard to treat. Some of precision medicine targets the gene mutations, so is therefore ineffective vs other cancers that occur from other mutations. It's why there are so many different oncology drugs treating the same organ that has cancer.
FTO is so huge because it is a regulator for many different pathways.
happy to be corrected if my interpretation is wrong
General Comments / Chat, page-6243
-
- There are more pages in this discussion • 5,641 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
0.000(0.00%) |
Mkt cap ! $270.9M | |||
| Open | High | Low | Value | Volume |
| $1.59 | $1.62 | $1.57 | $180.6K | 113.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 145 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 23400 | 1 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |